Drug interactions often involve CYP3A4 due to its broad substrate specificity. Inhibitors of CYP3A4 can lead to reduced metabolism of co-administered drugs, resulting in increased plasma levels and potential toxicity. Conversely, inducers of CYP3A4 can enhance drug metabolism, reducing the efficacy of the co-administered drugs.
